Abstract PS3-10-04: Characteristics of patients with HR+/HER2− early breast cancer eligible for adjuvant treatment with iCDK4/6: real-life evidence in a Colombian cancer center
Retrospective analysis finds significant eligibility for adjuvant iCDK4/6 in Colombian early breast cancer patients, suggesting broader clinical applications.
Key Points
This study aims to analyze the characteristics of patients with early HR+/HER2- breast cancer eligible for adjuvant treatment with CDK4/6 inhibitors.
Retrospective analysis of 334 patients with HR+/HER2- early breast cancer treated at a Colombian cancer center
Eligibility for abemaciclib and ribociclib assessed using specific criteria
Assessment of clinicopathological characteristics and treatment patterns.
36.2% of patients were eligible for abemaciclib, with 54.5% having ≥4 positive nodes
59% of patients were eligible for ribociclib, with 53.8% staged at III
Median age of patients was older than in pivotal trials (61 vs 51-58 years)
Lower prevalence of grade 3 tumors (17.1% vs 30-40% in trials)